146 results about "Cirrhosis" patented technology

A method for assessing nonalcoholic steatohepatitis (NASH) cirrhosis in a liver biopsy sample includes extracting, from the liver biopsy sample, image data indicative of one or more histopathological features, wherein the one or more histopathological features comprise septa and / or nodules and / or fibrosis, and analysing the extracted image data, using a machine learning model trained to assess the one or more histopathological features, to determine a degree of NASH cirrhosis. Training the machine learning model includes providing a plurality of training samples and a plurality of validation samples, each sample comprising a graded liver biopsy sample; quantifying parameters of the one or more histopathological features from image data of each of the training samples; selecting a subset of quantified parameters of the one or more histopathological features; constructing a model for assessing the one or more histopathological features from the subset of quantified parameters; and validating the constructed model using the validation samples.

A liver cirrhosis detection method based on ZOA-XGboost belongs to the technical field of medicine and machine learning, and comprises the following steps: (1) collecting patient information, and establishing a data set by using the information; (2) carrying out data analysis by utilizing Numpy, Pandas and Matplotlib, and optimizing a data set; (3) dividing the data set into a training set and a test set; (4) optimizing the gamma parameter of the XGboost by using a zebra optimization algorithm ZOA to obtain an optimal gamma parameter; (5) training a ZOA-XGboost detection model by using the training set to obtain a detection model; and (6) finally, inputting the test set into a ZOA-XGboost detection model, and outputting a liver cirrhosis detection result to realize detection. According to the method, the liver cirrhosis is detected based on the ZOA-XGBoost detection model, and the deep learning ability of the ZOA algorithm and the XGBoost is combined, so that the accuracy, the processing speed and the adaptability of liver cirrhosis diagnosis are improved.

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The invention discloses a portable ascites aspirator for cirrhosis, and relates to the technical field of ascites aspirates.The portable ascites aspirator for cirrhosis comprises a shell, a connecting pipe and a top plate; the device further comprises a suction assembly. The suction assembly comprises a water storage bag, a cleaning disc, a spray head, a guide rod, a driving motor, a cleaning pump, a connecting pipe, a suction bottle and a moving rod; the suction bottle is fixed in the shell and used for storing pumped liquid, the water storage bag is located at the top of the suction bottle, liquid used for cleaning the suction bottle is stored in the water storage bag, and the cleaning pump is fixed in the water storage bag; the nozzle is fixed at the edge of the cleaning disc, the cleaning disc is a hollow circular disc and is connected to the guide rod in a sliding manner, the guide rod is fixed in the suction bottle, and the cleaning disc is spirally connected to the moving rod; the water storage bag is an annular bag, and the connecting pipe penetrates through a round hole in the center of the water storage bag and extends into the suction bottle. The suction device can be cleaned in time, cross contamination is avoided, the suction device is cleaned under the condition that the suction device is not disassembled, and then the service life of the suction device is prolonged.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The present invention discloses phenyl-substituted dihydronaphthyridine compounds a preparation therefor and a use thereof, and belongs to the technical field of medicine. The compounds disclosed in the present invention are represented by formula I, and can be used as a mineralocorticoid receptor antagonist for treating, preventing or alleviating aldosteronism hyperplasia, diabetic nephropathy, hypertension, heart failure (comprising chronic heart failure, etc.), sequelae of myocardial infarction, liver cirrhosis, renal failure, stroke and other diseases in patients.

The invention discloses a cirrhosis ascites pressure dynamic measurement method and system, and relates to the technical field of medical auxiliary measurement. Comprising the following steps: acquiring an abdominal cavity image, ascites pressure dynamics and abdominal cavity blood flow pulsation data of a patient; extracting periodical fluctuation characteristics of the pressure data, and dynamically calibrating the image anatomical region according to the periodical fluctuation characteristics to obtain a candidate region; performing phase decorrelation analysis on the fluctuation characteristics of the region and the abdominal blood flow pulsation data to exclude a blood vessel adjacent region and obtain a target cavity region; based on this, a puncture path prediction model is constructed, and path data is output; finally, safety judgment is conducted on the path data, and when the pressure gradient of the path data is stable within the preset length range and meets the decorrelation condition, a puncture positioning point is output. The system comprises corresponding modules for executing the steps. Through multi-modal data fusion and dynamic analysis, precise planning and safety verification of puncture points are achieved, and the risk of accidentally injuring blood vessels and intestinal canals in the abdominal paracentesis is reduced.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The traditional Chinese medicine preparation for treating hepatopathy can be used for treating jaundice hepatitis, chronic hepatitis, alcoholic liver, liver injury, hepatitis B and early cirrhosis with symptoms such as hypochondriac swelling pain, inappetence, hypodynamia and abdominal fullness caused by uncomfortable liver qi and qi stagnation and blood stasis. In the treatment process of the hepatopathy, the action effect of the traditional Chinese medicine is slow and lasting, so that the raw material medicines are all crushed and prepared into the pill, the action time of the medicine is prolonged while the medicine effect is ensured, and the treatment of the hepatopathy is facilitated.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

Provided herein is a method of diagnosing or prognosing advanced liver fibrosis or liver cirrhosis in a patient. The method is accomplished by determining a score based on the circulating levels in serum of two markers.

The pharmaceutical composition for treating or preventing a fibrotic disease of the present invention contains a nucleic acid that inhibits the expression of mRNA encoding P4HA3. The fibrotic disease may be at least one disease selected from the group consisting of fibrosis, liver cirrhosis, renal failure, myocardial infarction, and cancer. The present invention provides a method for preventing or treating a fibrotic disease, which includes administering an effective amount of the pharmaceutical composition of the present invention to a subject suffering from or at risk of suffering from a fibrotic disease.

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The invention relates to an automatic preparation method and device of a medicament for treating liver cirrhosis. A traditional Chinese medicine decoction is prepared from the following raw materials in parts by weight: 10 parts of radix astragali, 5 parts of radix notoginseng, 15 parts of radix salviae miltiorrhizae, 10 parts of rhizoma atractylodis macrocephalae stir-fried with bran, 10 parts of poria cocos, 10 parts of fructus aurantii stir-fried with bran, 15 parts of vinegar turtle shell, 5 parts of vinegar schisandra chinensis, 15 parts of vinegar tortoise shell, 10 parts of peach kernel, 10 parts of radix curcumae, 15 parts of Chinese lobelia and 20 parts of phyllanthus urinaria. An automatic preparation device of the liver cirrhosis treatment medicament is applied, and the method comprises the following steps: S1, filling; s2, performing soaking; s3, decocting first; s4, group decoction; s5, later operation is carried out; s6, squeezing; a standardized decoction process aiming at a specific liver cirrhosis treatment prescription can be executed in a single container through exquisite mechanical linkage and automatic control in a whole process without manual intervention, and a specific traditional Chinese medicine formula (astragalus membranaceus, vinegar turtle shell and the like) is deeply combined with an automatic operation process of the device, so that a set of optimized preparation process is formed.

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

This AMPK activation composition comprises teadenol A.

The invention discloses a deuterium-depleted water composition containing plant exosomes as well as a preparation method and application of the deuterium-depleted water composition, and the deuterium-depleted water composition is prepared from the following raw materials in parts by weight: 3-18 parts of a prebiotic compound, 3-20 parts of a modified exosome composition, 1-7 parts of sodium alginate and 35-120 parts of deuterium-depleted water, wherein the modified exosome composition is prepared from the following raw materials: 1 to 10 parts of exosome composition, 0.5 to 7 parts of folium mori flavone, 0.5 to 5 parts of nano-selenium and 1 to 10 parts of trehalose. The invention relates to a deuterium-depleted water composition containing plant exosomes, in particular to a synergistic composition of plant-derived exosomes and deuterium-depleted water, which is used for enhancing the biological activity of the plant-derived exosomes and the deuterium-depleted water, and can be used for metabolic regulation of diseases such as hypertension, hyperglycemia, hyperlipidemia (three highs), cirrhosis and diabetic foot by combining with a prebiotic fiber compound and a mulberry leaf flavone-nano-selenium compound.

To provide a NLRP3 activity regulator.SOLUTION: An activity regulator is characterized by a compound of formula AA or a pharmaceutically acceptable salt thereof. The compound of formula AA is NLRP3 activity regulator, and therefore, can be used for the treatment of metabolic disorder (e.g., TYPE 2 diabetes mellitus, atherosclerosis, obesity or gout), disease of central nervous system (e.g., Alzheimer disease, multiple sclerosis, amyotrophic lateral sclerosis or Parkinson disease), lung disease (e.g., asthma, COPD or idiopathic pulmonary fibrosis), liver disease (e.g., NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g., acute pancreatitis or chronic pancreatitis), kidney disease (e.g., acute nephropathy or chronic nephropathy), intestinal disease (e.g., Crohn's disease or ulcerative colitis), dermatosis, musculoskeletal disease (e.g., scleroderma), vascular disease, bone disease, eye disease (e.g., glaucoma or macular degeneration), disease originated from virus infection, autoimmune disease, cancer or aging.SELECTED DRAWING: None

The present invention provides, in part, a novel small molecule PHD inhibitor, or a pharmaceutically acceptable salt thereof, having a structure according to Formula (A) and its sub-formula. Compounds provided herein are useful for the treatment of diseases, the diseases include heart diseases (e.g., ischemic heart disease, congestive heart failure and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease). # imgabs0 #

In one aspect, the disclosure provides a method for identifying whether a subject has or is at increased risk of developing a liver disease (e.g., non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hepatitis, cirrhosis, or cancer), comprising providing a cell-free deoxyribonucleic acid (cfDNA) sample derived from the subject, determining the cfDNA sample or a derivative thereof to determine a methylation pattern or methylation level of a DNA molecule of the cfDNA sample, processing the methylation pattern or methylation level using a trained machine learning (ML) algorithm to generate an output indicative of whether the cfDNA sample is positive for liver disease, and generating, based at least in part on the output, an electronic report indicating that the subject has a liver disease or an increased risk of developing a liver disease.

Provided are a bicyclic fused ring such as for example, benzo[d]imidazole, benzo[d][1,2,3]triazole, or 8-oxo-8,9-dihydro-7H-purine derivatives or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the bicyclic fused ring derivative or pharmaceutically acceptable salt thereof has an inhibitory activity against the lysyl oxidase family and can be usefully applied for preventing or treating various diseases associated with the lysyl oxidase family, such as idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), or liver cirrhosis.

The invention relates to compounds of formula (I), wherein R1 is selected from the group consisting of H, C1-3-alkyl, C1-3-haloalkyl, -CH2-CO-NH2, -CH2-CO-NHCH3 and -CH2-CO-N(CH3)2 R2 is selected from the group consisting of H, halogen, (C1-3)-alkyl and halo-(C1-3)-alkyl, R3 is selected from the group consisting of C1-3-alkyl, five- or six-membered heterocyclic ring with 1 to 3 heteroatoms selected from N, O, S or SO2 and a five- or six-membered carbocyclic ring, wherein R3 is substituted by one or two substituents R8 which are each independently selected from the group consisting of H, C1-3-alkyl, -CO-O-(C1-4-alkyl), halogen, CN, OH, O-C1-3-methyl and -CO-(C1-3-alkyl), wherein each V, U, Q and T are independently from each other selected from C or N, wherein R4 is selected from the group consisting of H, halogen, -methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R5 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R6 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R7 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, metabolic dysfunction associated Steatohepatitis (MASH), interstitial lung disease (ILD), decompensated liver cirrhosis and idiopathic pulmonary fibrosis (IPF).

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

The invention discloses a pharmaceutical preparation containing phenyl-substituted dihydronaphthyridine compounds and application, and belongs to the technical field of medicines. The pharmaceutical preparation disclosed by the invention can be used as a mineralocorticoid receptor antagonist, and is used for treating, preventing or relieving diseases such as overmuch aldosterone, diabetic nephropathy, hypertension, heart failure (including chronic heart failure and the like), sequelae of myocardial infarction, liver cirrhosis, renal failure, stroke and the like of patients.

A system for managing liver disease, the system comprising an electronic medical record system comprising a plurality of patient records. The system comprising a patient management platform configured to access the electronic medical record (EMR) system to retrieve medical records of one or more patients, analyze the medical records to selectively identify data related to a liver condition, interface with one or more data analysis platforms configured to receive and analyze the data related to a liver condition. Based on analysis by the patient management interface and / or the data analysis platforms, a display is generated comprising: specific liver-related patient attributes and conditions, and at least one of: a liver health prognosis or a recommended treatment for addressing the liver condition corresponding to the one or more patients. The liver condition can comprise one or more of: cancer, cirrhosis, liver failure, fatty liver disease, steatosis, ischemia, and / or hepatitis.

The present invention relates to 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).